Agree, the initial MC valuation when the pps was at 60c was way too high for a biotech start-up despite the market potential of all of IMU's IP. As with all biotech start-up, further positive clinical trial results will make the pps increase but the latest drop from 20c was clearly due to shorters and fundies rebalancing their position and also taking the opportunity of the recent CR at 20c to drop the pps further.......
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)